At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ANVS Annovis Bio, Inc.
Closed 03-18 16:00:00 EDT
2.47
-0.27
-9.85%
盘后2.48
+0.01+0.40%
18:31 EDT
High2.76Low2.45Vol658.29K
Open2.72D1 Closing2.74Amplitude11.06%
Mkt Cap70.04MTradable Cap59.92MTotal Shares28.36M
T/O1.66MT/O Rate2.71%Tradable Shares24.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)
TIPRANKS  ·  02:30
Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)
BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results
Reuters  ·  03-16 19:38
BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results
Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
TIPRANKS  ·  03-16 19:35
Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate
Benzinga  ·  03-16 19:33
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate
Annovis Bio Inc: Estimates That Its Current Cash and Cash Equivalents Will Enable It to Fund Its Operations Into Q3 of 2026
THOMSON REUTERS  ·  03-16 19:30
Annovis Bio Inc: Estimates That Its Current Cash and Cash Equivalents Will Enable It to Fund Its Operations Into Q3 of 2026
Press Release: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Dow Jones  ·  03-16 19:30
Press Release: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Bio FY 2025 net loss widens 17% to USD 28.86 million, interest income rises 111% to USD 0.7 million
Reuters  ·  03-14
Annovis Bio FY 2025 net loss widens 17% to USD 28.86 million, interest income rises 111% to USD 0.7 million
Annovis Bio to Present Twice at AD/PD 2026 International Conference
Reuters  ·  03-03
Annovis Bio to Present Twice at AD/PD 2026 International Conference
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
TIPRANKS  ·  02-21
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
TIPRANKS  ·  02-12
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
Annovis Bio Inc - Dsmb Finds No Safety Concerns, Trial to Continue as Planned
THOMSON REUTERS  ·  02-12
Annovis Bio Inc - Dsmb Finds No Safety Concerns, Trial to Continue as Planned
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
GlobeNewswire  ·  02-12
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
Annovis Bio Hosts Regulation FD Investor Information Webinar
TIPRANKS  ·  01-29
Annovis Bio Hosts Regulation FD Investor Information Webinar
Annovis Bio Launches 36-Month Study of Buntanetap in Parkinson's Patients
Reuters  ·  2025-12-19
Annovis Bio Launches 36-Month Study of Buntanetap in Parkinson's Patients
Annovis Bio Inc - to Begin Open-Label Extension Study in January 2026
THOMSON REUTERS  ·  2025-12-19
Annovis Bio Inc - to Begin Open-Label Extension Study in January 2026
Annovis Bio Inc. Hosts Corporate Update Webinar Featuring CEO Maria Maccecchini
Reuters  ·  2025-12-16
Annovis Bio Inc. Hosts Corporate Update Webinar Featuring CEO Maria Maccecchini
Annovis to Host Corporate Update Webinar on January 28, 2026
GlobeNewswire  ·  2025-12-16
Annovis to Host Corporate Update Webinar on January 28, 2026
Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares
Reuters  ·  2025-12-09
Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares
Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting
Reuters  ·  2025-12-03
Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting
Director Makes Bold Move with Major Annovis Bio Stock Purchase
TIPRANKS  ·  2025-11-26
Director Makes Bold Move with Major Annovis Bio Stock Purchase

Introduction

Company Name.
Annovis Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Issue price:
--